Page 402 - UK AirCrew Regulations (Consolidated) March 2022

Part MED - ANNEX IV - Medical

is likely to jeopardise the safe exercise of the privileges of the licence.
MED.B.085 AMC1 Dermatology
(a) If doubt exists about the fitness of applicants with eczema (exogenous and endogenous),
severe psoriasis, bacterial infections, drug induced, or bullous eruptions or urticaria, the
AME should refer the case to the medical assessor of the licensing authority.
(b) Systemic effects of radiant or pharmacological treatment for a dermatological condition
should be reviewed before a fit assessment may be considered.
(c) In cases where a dermatological condition is associated with a systemic illness, full
consideration should be given to the underlying illness before a fit assessment may be
considered.
MED.B.085 AMC2 Dermatology
In cases where a dermatological condition is associated with a systemic illness, full consideration
should be given to the underlying illness before a fit assessment may be considered.
MED.B.090 Oncology
(a) Before further consideration is given to their application, applicants with primary or
secondary malignant disease shall undergo satisfactory oncological evaluation. Such
applicants for a class 1 medical certificate shall be referred to the medical assessor of the
CAA. Such applicants for a class 2 medical certificate shall be assessed in consultation
with the medical assessor of the CAA.
(b) Applicants with a documented medical history or clinical diagnosis of an intracerebral
malignant tumour shall be assessed as unfit.
MED.B.090 AMC1 Oncology
(a) Applicants who have been diagnosed with a malignant disease may be assessed as fit
provided that:
(1) after primary treatment, there is no evidence of residual malignant disease likely to
jeopardise flight safety;
(2) time appropriate to the type of tumour and primary treatment has elapsed;
(3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment. Special
attention should be paid to applicants who have received anthracycline
chemotherapy;
(5) satisfactory oncology follow-up reports are provided to the medical assessor of the
licensing authority.
(b) An OML should be applied as appropriate.
(c) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as
unfit.
(d) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or
excised as necessary and there is regular follow-up.
MED.B.090 AMC2 Oncology
(a) Applicants who have been diagnosed with a malignant disease may be considered for a fit
assessment provided that:
(1) after primary treatment, there is no evidence of residual malignant disease likely to
jeopardise flight safety;
(2) time appropriate to the type of tumour and primary treatment has elapsed;
(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment that may
jeopardise flight safety;
(5) arrangements for an oncological follow-up have been made for an appropriate
period of time.
(b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as
unfit.
(c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or
excised as necessary and there is a regular follow-up.
MED.B.095 Medical examination and assessment of applicants for LAPL medical certificates
(a) An applicant for a LAPL medical certificate shall be assessed based on aero-medical best
practice.
(b) Special attention shall be given to the applicant's complete medical history.
(c) The initial assessment, all subsequent re-assessments after the licence holder reaches
the age of 50 and any assessments in cases where the medical history of the applicant is
not available to the examiner shall include at least all of the following:
(1) clinical examination;
(2) blood pressure;
(3) urine test;
(4) vision;
(5) hearing ability.
(d) After the initial assessment, subsequent re-assessments until the licence holder reaches
the age of 50 shall include at least both of the following:
(1) an assessment of the LAPL holder's medical history;
(2) the items specified in point(c) as deemed necessary by the AeMC, AME or GMP in
accordance with aero- medical best practice.
March 2022 402 of 554